Lectenz Bio receives a U01 from the NIH Common Fund Glycoscience program to further develop GlycoSenseTM technology.
Lectenz Bio receives an SBIR Phase I from the National Institute of General Medical Sciences (NIGMS) to develop additional Lectenz® specific for all N-Glycans.
